--- title: "First Coronary Stent at an ASC in Miami-Dade County | Amavita Research" url: https://md.amavitaresearch.com/blog/first-coronary-stent-ambulatory-surgery-center-miami-dade-2026 canonical: https://www.amavitaresearch.com/blog/first-coronary-stent-ambulatory-surgery-center-miami-dade-2026 schema_type: NewsArticle last_updated: 2026-05-13 --- # First Coronary Stent Deployed at an Ambulatory Surgery Center in Miami-Dade County *Published 13 May 2026 · News · ~4 min read* **Miami, FL — May 13, 2026.** Earlier today, Amavita Heart and Vascular Health® performed what we believe is the **first coronary stent procedure ever carried out at an ambulatory surgery center (ASC) in Miami-Dade County**. The percutaneous coronary intervention (PCI) was led by Dr. Pedro Martinez-Clark, Lead Investigator at Amavita Research Services LLC, at Amavita's Kendall ASC — the same facility that houses our cardiovascular Phase 1 clinical-trial unit. The patient was discharged the same day, fully recovered, and walked out of the facility without an overnight hospital stay — the central clinical promise of outpatient PCI. ## Why this matters For decades, coronary stenting in the United States was performed exclusively in hospital cath labs, with most patients admitted overnight for observation. In 2020, the Centers for Medicare & Medicaid Services (CMS) added PCI procedures to the ASC-payable list as part of the 2020 OPPS/ASC final rule (CMS-1717-FC), recognizing that select, well-screened patients could safely undergo coronary intervention in an outpatient setting and go home the same day. Since 2020, ASC-based PCI has expanded gradually across the country — but adoption in Florida, and specifically in Miami-Dade County, has been slow. Today's procedure is, to the best of our knowledge, the **first time a coronary stent has been deployed in an ASC anywhere in Miami-Dade County**. It is the result of three things coming together at the same facility: - A purpose-built cath-lab suite at Amavita's Kendall ASC, fluoroscopy-equipped and outfitted to current interventional cardiology standards. - Same-day recovery infrastructure — an eight-bed recovery suite where post-procedure patients can be observed before discharge, the same suite used by our Phase 1 trial unit. - A board-certified interventional cardiology team led by Dr. Pedro Martinez-Clark, with Dr. William O'Neill as Senior PI on cardiovascular research, and Dr. Hans Rutzen-Lopez on the electrophysiology side. ## What this signals to clinical-trial sponsors Beyond the clinical milestone, today's procedure is a proof point for sponsors evaluating Amavita as a cardiovascular trial site. The same combination — interventional capability, on-site recovery beds, an IRB-aware research operation — is exactly what device sponsors need for **early-feasibility, first-in-human (FIH), and pivotal cardiovascular device trials**. If your team is running a cardiovascular device trial — coronary stent, drug-coated balloon, intravascular imaging, structural heart, or peripheral intervention — and you need a site that can execute the procedure under both commercial and research protocols in the same building, with same-day discharge as a routine workflow rather than an exception, this is the kind of site you want. Amavita Research holds IAOCR GCSA recertification through 2028, making it one of the few cardiovascular clinical-trial sites in the United States with formal good-clinical-site-accreditation. Our broader cardiovascular trial-site capabilities are documented at https://www.amavitaresearch.com/capabilities and https://www.amavitaresearch.com/certifications, and our sister organization bioaccess® brings 18+ years of medical-device FIH trial execution in Latin America. ## About the procedure Out of respect for patient privacy, we are not disclosing patient demographics or clinical history. The case was selected and consented under Amavita's standard interventional cardiology screening protocol. Same-day discharge was planned in advance and executed without complication. ## Press contact For sponsor inquiries and press follow-ups about cardiovascular Phase 1 unit capability or ASC-based PCI at Amavita: **growth@amavita.health** ## Related links - Phase 1 trial unit: https://www.amavitaresearch.com/phase-1-unit - Operator profile: https://www.amavitaresearch.com/team/pedro-martinez-clark - Senior PI: https://www.amavitaresearch.com/team/william-oneill - Electrophysiology lead: https://www.amavitaresearch.com/team/hans-rutzen-lopez - Site certifications (GCSA + others): https://www.amavitaresearch.com/certifications - Cardiovascular site capabilities: https://www.amavitaresearch.com/capabilities - Sister organization (bioaccess® FIH CRO): https://www.amavitaresearch.com/sister-organization-bioaccess - 2026 GCSA recertification announcement: https://www.amavitaresearch.com/blog/amavita-research-iaocr-gcsa-recertification-2026 - News index: https://www.amavitaresearch.com/press